↓ Skip to main content

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Overview of attention for article published in JAMA Oncology, July 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news
5 news outlets
twitter
69 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
Published in
JAMA Oncology, July 2019
DOI 10.1001/jamaoncol.2019.0869
Pubmed ID
Authors

Bram De Laere, Prabhakar Rajan, Henrik Grönberg, Luc Dirix, Johan Lindberg

Twitter Demographics

The data shown below were collected from the profiles of 69 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 22%
Student > Ph. D. Student 4 17%
Other 3 13%
Student > Doctoral Student 2 9%
Student > Bachelor 2 9%
Other 1 4%
Unknown 6 26%
Readers by discipline Count As %
Medicine and Dentistry 7 30%
Biochemistry, Genetics and Molecular Biology 7 30%
Computer Science 1 4%
Sports and Recreations 1 4%
Arts and Humanities 1 4%
Other 1 4%
Unknown 5 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2021.
All research outputs
#329,559
of 17,601,811 outputs
Outputs from JAMA Oncology
#654
of 2,454 outputs
Outputs of similar age
#9,010
of 275,981 outputs
Outputs of similar age from JAMA Oncology
#32
of 98 outputs
Altmetric has tracked 17,601,811 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,454 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 78.8. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.